Actively Recruiting
Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
Led by Affiliated Hospital of Qinghai University · Updated on 2024-12-12
220
Participants Needed
1
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.
CONDITIONS
Official Title
Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Male or female aged 18 years or older
- Diagnosed with gastrointestinal or breast cancer by pathology
- Receiving capecitabine treatment for the first time
- Eastern Cancer Collaboration Group performance status of 0 to 2
- Receiving palliative or adjuvant chemotherapy with capecitabine (minimum daily dose 2000 mg/m2)
- Expected lifespan of at least 3 months
- Platelet count at least 100 x 10^9/L, white blood cell count above 3.0 x 10^9/L, hemoglobin at least 10.0 g/dL, normal liver and kidney function
- Using adequate contraception
You will not qualify if you...
- Previous use of capecitabine, liposome doxorubicin, or tyrosine kinase inhibitors causing HFS (e.g., sorafenib, sunitinib, apatinib)
- Initial capecitabine dose less than 800 mg/m2
- Radiation therapy or surgery within 4 weeks before treatment start
- Skin diseases that may interfere with trial results
- Known drug or alcohol abuse
- Pregnancy or lactation
- Participation in another clinical trial with investigational drug use within 30 days prior to treatment
- Fear of electroacupuncture stimulation or allergy to stainless steel needles or capecitabine components
- Receiving acupuncture or moxibustion with lymphedema in stimulated area
- Unresolved chemotherapy- or radiotherapy-related toxicities above grade 2 (except stable sensory neuropathy)
- Any unresolved skin toxicity from previous chemotherapy or radiotherapy except hair loss
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qinghai University Affiliated Hospital
Xining, Qinghai, China, 810000
Actively Recruiting
Research Team
J
Jiuda Zhao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here